New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert
暂无分享,去创建一个
[1] T. Merriman,et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] J. O'dell,et al. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. , 2018, Contemporary clinical trials.
[3] Kenneth G Saag,et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.
[4] D. Solomon,et al. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. , 2018, Journal of the American College of Cardiology.
[5] M. Bredemeier,et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials , 2018, BMC Cardiovascular Disorders.
[6] C. Pepine,et al. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view , 2017, Clinical cardiology.
[7] Hyon K. Choi,et al. Effects of Febuxostat in Early Gout , 2017, Arthritis & rheumatology.
[8] J. Foody,et al. Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. , 2017, American health & drug benefits.
[9] J. Singh,et al. Medication adherence among patients with gout: A systematic review and meta-analysis. , 2017, Seminars in arthritis and rheumatism.
[10] N. Dalbeth,et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study , 2017, Annals of the rheumatic diseases.
[11] K. Jordan,et al. The British Society for Rheumatology Guideline for the Management of Gout. , 2017, Rheumatology.
[12] L. Duley,et al. OP0268 Nurse-led care versus general practitioner care of people with gout: a uk community-based randomised controlled trial , 2017 .
[13] J. Singh,et al. Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data , 2017, BMC Medicine.
[14] N. Dalbeth,et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout , 2017, Annals of the rheumatic diseases.
[15] K. Saag,et al. Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study) , 2017, Arthritis & rheumatology.
[16] T. Asano,et al. Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis , 2016, Mediators of inflammation.
[17] A. So,et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) , 2016, Annals of the rheumatic diseases.
[18] C. Hawkey,et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study , 2016, BMJ Open.
[19] J. Danesh,et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. , 2016, Journal of the American College of Cardiology.
[20] E. Kelley. A new paradigm for XOR-catalyzed reactive species generation in the endothelium , 2015, Pharmacological reports : PR.
[21] R. de Caterina,et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia , 2014, BMJ Open.
[22] F. Becce,et al. 2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.
[23] A. So,et al. Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice , 2014, Scientific Reports.
[24] L. Abenhaim,et al. Impact of allopurinol on risk of myocardial infarction , 2014, Annals of the rheumatic diseases.
[25] C. Bombardier,et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative , 2013, Annals of the rheumatic diseases.
[26] Charles King,et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.
[27] W. White,et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. , 2012, American heart journal.
[28] Y. Chen,et al. Impact of allopurinol use on urate concentration and cardiovascular outcome , 2011, British journal of clinical pharmacology.
[29] M. Barclay,et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. , 2011, Arthritis and rheumatism.
[30] J. Singh. Advances in gout: some answers, more questions , 2010, Arthritis research & therapy.
[31] H. Schumacher,et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.
[32] H. Schumacher,et al. Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout , 2009, The Journal of Rheumatology.
[33] H. Schumacher,et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.
[34] H. Schumacher,et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. , 2008, Rheumatology.
[35] H. Schumacher,et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.
[36] M. Becker,et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. , 2005, Life sciences.
[37] H. Schumacher,et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. , 2005, Arthritis and rheumatism.
[38] M. Barclay,et al. How to prevent allopurinol hypersensitivity reactions? , 2018, Rheumatology.
[39] K. Jordan,et al. The British Society for Rheumatology Guideline for the Management of Gout. , 2017, Rheumatology.
[40] I. Hisatome,et al. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. , 2017, Journal of cardiology.
[41] K. Jordan,et al. The British Society for Rheumatology Guideline for the Management of Gout. , 2017, Rheumatology.